BOSTON SCIENTIFIC CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.49 USD | +1.56% |
|
-0.40% | +18.29% |
| Apr. 15 | Integer Holdings to Benefit from Pulsed Field Ablation Market Growth, BofA Says | MT |
| Apr. 15 | Truist Securities Adjusts Boston Scientific Price Target to $79 From $73, Buy Rating Kept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
67.44
USD
Average target price
73.18
USD
Spread / Average Target
+8.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.29% | 99.13B | |
| +4.50% | 213B | |
| +3.92% | 177B | |
| +12.93% | 134B | |
| +0.11% | 63.47B | |
| +17.67% | 53.69B | |
| -4.51% | 46.36B | |
| -1.25% | 41.09B | |
| +11.05% | 39.3B | |
| +7.82% | 27.19B |
- Stock Market
- Equities
- BSX Stock
- News Boston Scientific Corporation
- Truist Securities Adjusts Price Target on Boston Scientific to $54 From $50, Maintains Buy Rating
